Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| ID | DOID:1791 |
| Name | peritoneal carcinoma |
| Definition | A peritoneum cancer that is located_in the inside of the abdomen. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer peritoneum cancer peritoneal carcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT00565851 | Phase III | Gemcitabine Docetaxel + Paclitaxel Carboplatin Bevacizumab | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | 2 |
| NCT00954174 | Phase III | Carboplatin + Paclitaxel Ifosfamide + Paclitaxel | Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritorium Cavity Cancer | Unknown status | USA | 1 |
| NCT00989651 | Phase I | Bevacizumab + Veliparib Carboplatin Paclitaxel Cisplatin | Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Completed | USA | 0 |
| NCT00993655 | Phase III | Cisplatin Paclitaxel Carboplatin | Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Completed | USA | GBR | ESP | CAN | 0 |
| NCT01012817 | Phase Ib/II | Topotecan + Veliparib | Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
| NCT01031381 | Phase II | Bevacizumab + Everolimus | Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer | Completed | USA | 0 |
| NCT01061515 | Phase I | Capecitabine Bevacizumab Oxaliplatin | Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer | Active, not recruiting | USA | 0 |
| NCT01132014 | Phase I | Bevacizumab Dacarbazine | Autologous OC-DC Vaccine in Ovarian Cancer | Completed | USA | 0 |
| NCT01145430 | Phase I | Pegylated liposomal doxorubicin + Veliparib | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer | Completed | USA | 0 |
| NCT01146795 | Phase II | Bevacizumab + Carboplatin + Paclitaxel | Neoadjuvant Therapy for Ovarian Cancer | Completed | USA | 0 |
| NCT01239732 | Phase III | Bevacizumab + Carboplatin + Paclitaxel | A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer | Completed | NLD | ITA | FRA | ESP | CAN | AUT | 31 |
| NCT01248962 | Phase II | Carboplatin | Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer | Completed | USA | 0 |
| NCT01264432 | Phase I | Veliparib | Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer | Completed | USA | CAN | 0 |
| NCT01281514 | Phase I | Carboplatin + Everolimus + Pegylated liposomal doxorubicin | Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | Completed | USA | 0 |
| NCT01305213 | Phase Ib/II | Fosbretabulin Bevacizumab | Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | Completed | USA | 0 |
| NCT01312376 | Phase I | Fludarabine Cyclophosphamide Bevacizumab CD3/CD28 stimulated/primed autologous Ts OC-DC vaccine | Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer | Terminated | USA | 0 |
| NCT01357161 | Phase II | Carboplatin Adavosertib Paclitaxel | A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) | Completed | 0 | |
| NCT01445418 | Phase I | Olaparib Carboplatin | AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer | Completed | USA | 0 |
| NCT01459380 | Phase I | Carboplatin Doxorubicin Veliparib Bevacizumab | Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Completed | USA | 0 |
| NCT01493505 | Phase III | Carboplatin Paclitaxel Trebananib | TRINOVA-3 | Terminated | USA | NLD | ITA | ESP | DEU | CAN | BEL | AUT | 6 |
| NCT01519869 | Phase I | Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma | Completed | USA | 0 | |
| NCT01535157 | Phase Ib/II | Ketoconazole Fenretinide | Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer | Terminated | USA | 0 |
| NCT01579812 | Phase II | Metformin | Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients | Completed | USA | 0 |
| NCT01607905 | Phase I | Selinexor | Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer | Completed | USA | CAN | 1 |
| NCT01652079 | Phase II | Bevacizumab + NLG207 | CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer | Completed | USA | 0 |
| NCT01669798 | Phase II | Nintedanib | BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer | Completed | USA | 0 |
| NCT01849874 | Phase III | Binimetinib | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Terminated | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 8 |
| NCT01936974 | Phase II | Bevacizumab + Cisplatin + Gemcitabine Bevacizumab + Gemcitabine + Oxaliplatin Bevacizumab + Carboplatin + Gemcitabine Bevacizumab + Gemcitabine | (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma | Terminated | USA | 0 |
| NCT01974765 | Phase II | Enzalutamide | Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies | Completed | USA | 0 |
| NCT02050009 | Phase I | Carboplatin + Metformin + Paclitaxel | Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Withdrawn | USA | 0 |
| NCT02059265 | Phase II | Dasatinib | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer | Terminated | USA | 0 |
| NCT02091999 | Phase I | Enfortumab vedotin-ejfv | A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 | Completed | USA | CAN | 0 |
| NCT02101775 | Phase II | Gemcitabine Adavosertib + Gemcitabine | Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | CAN | 1 |
| NCT02101788 | Phase II | Topotecan Letrozole + Paclitaxel + Pegylated liposomal doxorubicin + Tamoxifen Trametinib | Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer | Active, not recruiting | USA | GBR | 0 |
| NCT02121990 | Phase I | Bevacizumab + Cisplatin + Olaparib + Paclitaxel | Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | Completed | USA | 0 |
| NCT02122185 | Phase II | Metformin Carboplatin + Docetaxel + Paclitaxel | Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Suspended | USA | 0 |
| NCT02166905 | Phase Ib/II | Poly ICLC Rasdegafusp alfa Epacadostat | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | Completed | USA | 0 |
| NCT02188550 | Phase II | Everolimus + Letrozole | Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer | Unknown status | USA | 0 |
| NCT02208375 | Phase Ib/II | Capivasertib + Olaparib Olaparib + Vistusertib | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian | Active, not recruiting | USA | 0 |
| NCT02275039 | Phase I | MVAp53 Gemcitabine | p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer | Completed | USA | 0 |
| NCT02283658 | Phase II | Everolimus + Letrozole | Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | Completed | USA | 0 |
| NCT02312245 | Phase II | Topotecan Doxorubicin Paclitaxel Gemcitabine | Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Completed | USA | 0 |
| NCT02316834 | Phase I | Talazoparib | POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer | Completed | USA | 0 |
| NCT02392676 | Phase III | Olaparib | Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations | Withdrawn | USA | GBR | 3 |
| NCT02431559 | Phase Ib/II | Aldoxorubicin + Durvalumab + Motolimod | A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated | Completed | USA | 1 |
| NCT02440425 | Phase II | Paclitaxel Pembrolizumab | Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | Completed | USA | 0 |
| NCT02446600 | Phase III | Cediranib + Olaparib Olaparib Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin | Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | CAN | 2 |
| NCT02459301 | Phase I | Monalizumab | Dose-Ranging Study of IPH2201 in Patients With High Grade Serious CA of Ovarian, Fallopian Tube or Peritoneal Origin | Completed | CAN | 0 |
| NCT02470585 | Phase III | Carboplatin Paclitaxel Veliparib | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Terminated | USA | NZL | GBR | ESP | AUS | 6 |
| NCT02485990 | Phase Ib/II | Olaparib Tremelimumab | Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) | Terminated | USA | 0 |
| NCT02537444 | Phase II | Acalabrutinib Pembrolizumab | ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191) | Completed | USA | 0 |
| NCT02571725 | Phase Ib/II | Olaparib + Tremelimumab | PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | Active, not recruiting | USA | 0 |
| NCT02608684 | Phase II | Cisplatin + Gemcitabine + Pembrolizumab | A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer | Completed | USA | 0 |
| NCT02657928 | Phase II | Letrozole + Ribociclib | Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer | Completed | USA | 0 |
| NCT02659241 | Phase I | Adavosertib | A Pilot Study of Induction Wee1 Inhibition in Ovarian Cancer | Active, not recruiting | USA | 0 |
| NCT02661815 | Phase I | Paclitaxel + Ricolinostat Bevacizumab | A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer | Terminated | USA | 0 |
| NCT02764333 | Phase II | Durvalumab + TPIV 200 | TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer | Completed | USA | 0 |
| NCT02833506 | Phase I | NY-ESO-1 peptide vaccine + Sirolimus NY-ESO-1 peptide vaccine | Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Withdrawn | USA | 0 |
| NCT02834975 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab | Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). | Terminated | USA | 0 |
| NCT02889900 | Phase II | Cediranib + Olaparib | Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO) | Completed | USA | 0 |
| NCT02901899 | Phase II | Guadecitabine + Pembrolizumab | Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Completed | USA | 0 |
| NCT02922764 | Phase I | RGX-104 Ipilimumab + RGX-104 Nivolumab + RGX-104 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RGX-104 | A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma | Recruiting | USA | 0 |
| NCT02953457 | Phase II | Durvalumab + Olaparib + Tremelimumab | Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation | Active, not recruiting | USA | 0 |
| NCT03017131 | Phase I | Aldesleukin + Cyclophosphamide + Decitabine + NY-ESO-1-c259T | Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | 0 |
| NCT03029403 | Phase II | Cyclophosphamide + Maveropepimut-S + Pembrolizumab | Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer | Active, not recruiting | CAN | 0 |
| NCT03038100 | Phase III | Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel | A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050) | Completed | USA | ITA | FRA | ESP | DEU | BEL | AUT | AUS | 14 |
| NCT03054298 | Phase I | HuCART-meso cells Cyclophosphamide | CAR T Cells in Mesothelin Expressing Cancers | Active, not recruiting | USA | 0 |
| NCT03054909 | Phase I | ALT-803 | QUILT-2.021: Phase I of IP Followed by SQ ALT-803 for Ovarian Cancer | Completed | USA | 0 |
| NCT03079687 | Expanded access | Olaparib | Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | Approved for marketing | USA | 0 |
| NCT03134638 | Phase I | Carboplatin + SY-1365 SY-1365 Fulvestrant + SY-1365 | A Study of SY-1365 in Adult Patients With Advanced Solid Tumors | Terminated | USA | FRA | CAN | 0 |
| NCT03162562 | Phase I | Oregovomab + Poly ICLC | The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer | Terminated | USA | 0 |
| NCT03206047 | Phase Ib/II | Atezolizumab + Guadecitabine Atezolizumab Atezolizumab + Guadecitabine + Rasdegafusp alfa | Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
| NCT03206645 | Phase I | Carboplatin + Paclitaxel + PTC596 | PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy | Completed | USA | 0 |
| NCT03246074 | Phase I | Fostamatinib + Paclitaxel | Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer | Active, not recruiting | USA | 0 |
| NCT03278717 | Phase III | Olaparib Cediranib + Olaparib | Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients (ICON9) | Recruiting | NZL | GBR | CAN | AUS | 0 |
| NCT03319628 | Phase I | XMT-1536 | First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | Active, not recruiting | USA | 0 |
| NCT03348631 | Phase II | Tazemetostat | Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer | Active, not recruiting | USA | 0 |
| NCT03355976 | Phase II | Ipilimumab + Nivolumab Nivolumab | BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas | Active, not recruiting | USA | 0 |
| NCT03394885 | Phase Ib/II | Atezolizumab + Carboplatin + Paclitaxel | Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer (AdORN) | Completed | USA | 0 |
| NCT03410784 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab | Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer (MITO28MaNGOov4) | Recruiting | ITA | 0 |
| NCT03462342 | Phase II | Ceralasertib + Olaparib | Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer (CAPRI) | Recruiting | USA | 0 |
| NCT03531645 | Phase II | Fulvestrant + Palbociclib | Fulvestrant Plus Palbociclib in Women With Advanced Low Grade Serous Carcinoma | Active, not recruiting | USA | 0 |
| NCT03596281 | Phase I | Pegylated liposomal doxorubicin + Pembrolizumab Bevacizumab + Pembrolizumab | Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer (PEMBOV) | Active, not recruiting | FRA | 0 |
| NCT03598270 | Phase III | Carboplatin + Gemcitabine Niraparib Carboplatin + Pegylated liposomal doxorubicin Atezolizumab + Carboplatin + Pegylated liposomal doxorubicin Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel Atezolizumab + Niraparib | Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA) | Active, not recruiting | ITA | FRA | ESP | DEU | BEL | 0 |
| NCT03673124 | Phase II | Letrozole + Ribociclib | Ribociclib and Letrozole Treatment in Ovarian Cancer | Active, not recruiting | USA | 0 |
| NCT03691376 | Phase I | Melphalan NY-ESO-1 TCR CD4- CD34+ HSC Aldesleukin Autologous NY-ESO-1-specific CD8-positive T cells | Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
| NCT03734692 | Phase Ib/II | Cisplatin + Pembrolizumab + Rintatolimod | Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer | Recruiting | USA | 0 |
| NCT03735589 | Phase Ib/II | alphaDC1 + NK-like CTLs | Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Withdrawn | USA | 0 |
| NCT03839524 | Phase I | TG4050 | A Trial Evaluating TG4050 in Ovarian Carcinoma. | Active, not recruiting | USA | FRA | 0 |
| NCT03924245 | Phase Ib/II | Entinostat Entinostat + Olaparib | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers | Terminated | USA | 0 |
| NCT04095364 | Phase III | Carboplatin + Letrozole + Paclitaxel Letrozole | Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian or Primary Peritoneal Cancer | Recruiting | USA | CAN | 2 |
| NCT04205227 | Phase Ib/II | ENB003 + Pembrolizumab | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | Active, not recruiting | USA | AUS | 0 |
| NCT04498117 | Phase III | Carboplatin + Oregovomab + Paclitaxel Carboplatin + Paclitaxel | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (FLORA-5) | Active, not recruiting | USA | ITA | ESP | CAN | BEL | 9 |
| NCT04516447 | Phase I | Pegylated liposomal doxorubicin + ZN-c3 Carboplatin + ZN-c3 | A Study of ZN-c3 in Patients With Platinum-Resistant Ovarian Cancer | Recruiting | USA | AUS | 5 |
| NCT04570839 | Phase Ib/II | BMS-986207 + COM701 + Nivolumab Nivolumab | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | Active, not recruiting | USA | 0 |
| NCT04625270 | Phase II | Defactinib + RO5126766 RO5126766 | A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation (RAMP 201) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CAN | BEL | 0 |
| NCT04657068 | Phase Ib/II | ART0380 + Gemcitabine ART0380 Gemcitabine | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | Recruiting | USA | GBR | FRA | ESP | 0 |
| NCT04706962 | Phase I | TH1902 | TH1902 in Patients With Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
| NCT04787289 | Phase II | Bevacizumab | A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer | Recruiting | CAN | 0 |
| NCT04887961 | Phase II | Pegylated liposomal doxorubicin + Trabectedin | Reprab Study: PLD + Trabectedin Rechallenge (MITO36) | Unknown status | ITA | 0 |
| NCT04918186 | Phase II | BA3021 + Durvalumab Durvalumab + Mecbotamab Vedotin | Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC) | Recruiting | USA | CAN | 0 |
| NCT05032040 | Phase II | XmAb20717 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | Recruiting | USA | 0 |
| NCT05116189 | Phase III | Bevacizumab + Docetaxel Bevacizumab + Paclitaxel + Pembrolizumab Bevacizumab + Docetaxel + Pembrolizumab Bevacizumab + Paclitaxel | Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) | Active, not recruiting | USA | NZL | NLD | ITA | GBR | FRA | DEU | CAN | BEL | AUS | 15 |
| NCT05199272 | Phase Ib/II | 23ME-00610 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | Active, not recruiting | USA | CAN | 0 |
| NCT05257408 | Phase III | Nab-paclitaxel Nab-paclitaxel + Relacorilant | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS | 6 |
| NCT05261490 | Phase Ib/II | Pegylated liposomal doxorubicin + TTI-622 | Study of TTI-622 in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer | Terminated | USA | 0 |
| NCT05358639 | Phase I | Navitoclax + Olaparib | Combination of Olaparib and Navitoclax in Women With HGSC and TNBC | Recruiting | CAN | 0 |
| NCT05394675 | Phase I | DS-9606a | A Study of DS-9606a in Patients With Advanced Solid Tumors | Recruiting | USA | GBR | 0 |
| NCT05465941 | Phase II | PLX038 | PLX038 for the Treatment of Patients With Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | Recruiting | USA | 0 |
| NCT05564377 | Phase II | Selumetinib Binimetinib + Fulvestrant Binimetinib + Palbociclib Nilotinib + Paclitaxel Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin Panitumumab + Sotorasib Binimetinib Fulvestrant Olaparib Olaparib + Selumetinib Alpelisib + Olaparib Neratinib Neratinib + Palbociclib Fluorouracil + Leucovorin + Oxaliplatin Ipatasertib + Paclitaxel | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Recruiting | USA | 1 |
| NCT05601700 | Phase III | Carboplatin + Paclitaxel Letrozole | Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial) (LEPRE) | Recruiting | ITA | 0 |
| NCT05636111 | Phase I | Bevacizumab + Lurbinectedin + Paclitaxel | Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer | Recruiting | USA | 0 |
| NCT05739981 | Phase II | Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + GEN-1 + Paclitaxel | A Phase II Study Evaluating the Effect of GEN-1 on SLL When Administered in Combination With Bevacizumab and NACT in Subjects Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer (MRD) | Recruiting | USA | 0 |
| NCT05756907 | Phase Ib/II | Atezolizumab + SON-1010 SON-1010 | Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer | Recruiting | USA | AUS | 0 |
| NCT05836324 | Phase I | INCA33890 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | 2 |
| NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
| NCT05961124 | Phase II | Niraparib | Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer | Recruiting | CAN | 0 |
| NCT05983276 | Phase II | Carboplatin + Decitabine + Paclitaxel + Selinexor Carboplatin + Decitabine + Paclitaxel | Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer | Recruiting | USA | 0 |
| NCT06028932 | Phase II | Sacituzumab govitecan-hziy | A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients | Recruiting | USA | 0 |
| NCT06065462 | Phase Ib/II | Dostarlimab-gxly + LB-100 | Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 | Recruiting | USA | 0 |
| NCT06136884 | Phase I | AO-252 | A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT06334432 | Phase Ib/II | NUV-1511 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | Recruiting | USA | 0 |